developmental neurological evaluations and treatment, p.c

1 fulton avenue, suite 120
hempstead, new york 11550

NYS Entity Status
ACTIVE

NYS Filing Date
JANUARY 24, 2014

NYS DOS ID#
4519119

County
NASSAU

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2014 - DEVELOPMENTAL NEUROLOGICAL EVALUATIONS AND TREATMENT, P.C









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • New Approvals Show FDA Is Adapting to Precision Medicine
    By Frank Vinluan - Tuesday May 30, 2017

    The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new experimental treatments. Randomized trials are long, expensive to run, and ultimately produce limited answers, she said at a medical conference last week. The […]

    Source: Xconomy New York
  • Cracking Down on Dissent, Egypt Enacts Law Regulating NGOs
    By webmaster@philanthropynewsdigest.org (Matt Sinclair) - Friday Jun 2, 2017

    The Egyptian lawmakers have passed a bill that restricts NGO activity in the country to developmental and social work....

    Source: Philanthropy News Digest (PND)
  • Bladder Sparing Trimodal Therapy Evaluated for Clinical Efficacy in Retrospective Study
    Tuesday May 23, 2017

    The recurrence rate for cystectomy was 38% compared to 59% for TMT.

    Source: The Doctor's Channel
  • Deficits in Cellular Recycling May Be Key in Better Understanding Parkinson’s Disease
    Wednesday May 31, 2017

    “It’s a time of tremendous revolution in Parkinson’s disease,” says Un J. Kang, MD, H. Houston Merritt Professor of Neurology and Chief of the Division of Movement Disorders at Columbia University Medical Center. Significant progress has been made in understanding the multifactorial pathogenesis of this neurodegenerative disease, with a focus on genetic and environmental factors, -

    Source: The Doctor's Channel
  • Expanding Teladoc Adds Network, Tech With $440M Best Doctors Deal
    By David Holley - Tuesday Jun 20, 2017

    Dallas—In Teladoc’s acquisition of Boston-based Best Doctors—a $440 million cash-and-stock deal that the companies announced Monday—Teladoc (NYSE: TDOC) is gaining a business that lets it offer more specialization in its telemedicine services. Best Doctors connects individuals who have tough decisions to make about treatments—or who want a second opinion about a diagnosis—with top-rated doctors worldwide. […]

    Source: Xconomy New York
  • Expanding Teladoc Adds Network, Tech With $440M Best Doctors Deal
    By David Holley - Monday Jun 19, 2017

    Dallas—In Teladoc’s acquisition of Boston-based Best Doctors—a $440 million cash-and-stock deal that the companies announced Monday—Teladoc (NYSE: TDOC) is gaining a business that lets it offer more specialization in its telemedicine services. Best Doctors connects individuals who have tough decisions to make about treatments—or who want a second opinion about a diagnosis—with top-rated doctors worldwide. […]

    Source: Xconomy VC, Deals, & Startups Feed
  • 8 Best Practices For Evaluating A Programmatic TV Platform
    Monday Mar 20, 2017

    As more advertisers and their media agencies evaluate tactics for implementing programmatic TV (PTV), what should they look for in PTV vendors? Media buyers at Los Angeles-based agency Quigley-Simpsonoffered best practices during MediaPost's TV Insider Summit in Scottsdale, Arizona.

    Source: Media Post: Show Daily
  • Adamis Obtains FDA Approval for Epinephrine Treatment
    Thursday Jun 15, 2017

    Adamis Pharmaceuticals said federal regulators have given it a green light to produce Symjepi, an emergency injection treatment for allergic reactions, providing a potential competitor to Mylan NV’s EpiPen.

    Source: The Wall Street Journal: U.S. Business